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Epidemiological cutoff values (ECVs) for the Cryptococcus neoformans-Cryptococcus gattii species complex versus fluconazole,
itraconazole, posaconazole, and voriconazole are not available. We established ECVs for these species and agents based on wild-
type (WT)MIC distributions. A total of 2,985 to 5,733 CLSI MICs for C. neoformans (including isolates of molecular type VNI
[MICs for 759 to 1,137 isolates] and VNII, VNIII, and VNIV [MICs for 24 to 57 isolates]) and 705 to 975 MICs for C. gattii (in-
cluding 42 to 260 for VGI, VGII, VGIII, and VGIV isolates) were gathered in 15 to 24 laboratories (Europe, United States, Argen-
tina, Australia, Brazil, Canada, Cuba, India, Mexico, and South Africa) and were aggregated for analysis. Additionally, 220 to 359
MICs measured using CLSI yeast nitrogen base (YNB) medium instead of CLSI RPMImedium for C. neoformanswere evaluated.
CLSI RPMImedium ECVs for distributions originating from at least three laboratories, which included>95% of the modeled
WT population, were as follows: fluconazole, 8g/ml (VNI, C. gattii nontyped, VGI, VGIIa, and VGIII), 16g/ml (C. neofor-
mans nontyped, VNIII, and VGIV), and 32g/ml (VGII); itraconazole, 0.25g/ml (VNI), 0.5g/ml (C. neoformans and C. gat-
tii nontyped and VGI to VGIII), and 1g/ml (VGIV); posaconazole, 0.25g/ml (C. neoformans nontyped and VNI) and 0.5
g/ml (C. gattii nontyped and VGI); and voriconazole, 0.12 g/ml (VNIV), 0.25 g/ml (C. neoformans and C. gattii nontyped,
VNI, VNIII, VGII, and VGIIa,), and 0.5g/ml (VGI). The number of laboratories contributing data for other molecular types
was too low to ascertain that the differences were due to factors other than assay variation. In the absence of clinical breakpoints,
our ECVsmay aid in the detection of isolates with acquired resistance mechanisms and should be listed in the revised CLSI
M27-A3 and CLSI M27-S3 documents.
The Cryptococcus neoformans-Cryptococcus gattii complex is themost common species of non-Candida yeasts recovered from
clinical specimens (32.9% of 8,717 isolates) (41). In addition,
cryptococcal disease has been reported as the second most com-
mon severe fungal infection in certain regions (41). Infections
caused by C. neoformans var. grubii (serotype A) and, to a lesser
degree, by C. neoformans var. neoformans (serotype D) are seen
worldwide among immunocompromised hosts (4). The more
geographically restricted C. gattii (serotypes B and C) causes in-
fections among immunocompromised as well as nonimmuno-
compromised patients, and the infections are more difficult to
treat (27, 38). Irrespective of the species, cryptococcal disease is
associated with high mortality rates (12.7%) (15, 17, 38). Using
molecular methodologies, eight major molecular types have been
identified among the four serotypes and their hybrids (4, 6, 8, 25,
31, 51). C. neoformans comprises molecular types VNI and VNII
(both serotype A), VNIII (serotype A/D hybrid), and VNIV (se-
rotype D), while C. gattii comprises VGI, VGII, and VGIV (all
serotype B), VGII, and VGIV (both serotype C) (25). Molecular
type VGII has been of particular interest in recent years due to the
emergence of the novel subtypes VGIIa, VGIIb, and VGIIc; mo-
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lecular types VNI to VNIV and VGI to VGIV also have been des-
ignated AFLP1 to AFLP3 and AFLP4 to AFLP7, respectively (4, 6,
7). Identification of these different molecular types has been asso-
ciated with differences in antifungal susceptibility and virulence
(4, 6–11, 22, 25, 33, 51).
In addition to the different amphotericin B formulations, flu-
conazole and itraconazole are recommended as primary alterna-
tive induction treatments for infections caused by C. neoformans
and C. gattii and voriconazole and posaconazole as salvage con-
solidation therapies (35, 38); fluconazole is also the drug of choice
for lifelong suppressive (maintenance) therapy or primary ther-
apy in some areas (24). The azoles block the pathway of ergosterol
biosynthesis by inhibiting the 14--lanosterol demethylase en-
zyme, which is coded by the CYP51 gene in C. neoformans
(CnCYP51; also called ERG11) (46). The wide use of fluconazole
and other triazoles has led to in vitro resistance among Candida
and Cryptococcus isolates, especially to fluconazole more than to
the newer triazoles, voriconazole, and posaconazole (38). Two
azole resistance mechanisms have been identified in C. neofor-
mans (18, 32, 46, 54).
The use of standard testing methods has allowed the recog-
nition of antifungal resistance, as well as the proposal of clinical
breakpoints (CBPs) for Candida spp. and epidemiological cut-
off values (ECVs) for Aspergillus spp. by the Clinical and Lab-
oratory Standards Institute (CLSI) and the European Commit-
tee for Antimicrobial Susceptibility Testing (AFST-EUCAST)
(19–21, 40, 42, 44, 47). More recently, CLSI amphotericin B
and flucytosine ECVs were defined for the Cryptococcus neofor-
mans-Cryptococcus gattii species complex (22). CBPs are based
on MIC distributions, pharmacokinetic and pharmacody-
namic (PK/PD) parameters, animal studies, and clinical out-
comes to therapy, while the ECV is based mostly on MIC dis-
tributions. Numerous surveys indicate that CLSIMICs are16
g/ml (fluconazole) and0.5g/ml (the other three triazoles)
for most C. neoformans and C. gattii isolates (5, 9, 10, 16, 24, 43,
50). In the last few years, azole (mostly fluconazole) antifungal
susceptibility differences have been reported for these two spe-
cies and for their molecular types and serotypes (10, 11, 25, 33,
50, 51). However, CBPs or ECVs based on data from multiple
laboratories are not available for either C. neoformans or C.
gattii versus the triazoles. ECVs defined in the present study
could help to characterize the susceptibility of these species and
to monitor the emergence of strains with mutations that could
lead to reduced antifungal susceptibility to fluconazole, itra-
conazole, posaconazole, and voriconazole.
The purpose of the studywas dual: (i) to definewild-type (WT;
population of isolates in a species-drug combination with no de-
tectable acquired resistance mechanisms) (14, 52) susceptibility
endpoint distributions of each species/molecular type and triazole
combination originating from at least 3 laboratories and (ii) to
propose ECVs (highest WT susceptibility endpoint) of four tria-
zoles.We aggregated theCLSI RPMI brothmicrodilutionMICs of
fluconazole, itraconazole, posaconazole, and voriconazole ob-
tained in 15 to 24 laboratories (2,985 to 5,733 MICs for C. neofor-
mans and 705 to 975 MICs for C. gattii [species/molecular type
and agent/combination dependent]) in Europe, theUnited States,
Argentina, Australia, Canada, Cuba, Brazil, India, Mexico, and
South Africa. The 220 to 359 MICs that were obtained using the
alternative CLSI yeast nitrogen base (YNB) broth (12, 13) for C.
neoformans were analyzed separately.
MATERIALS AND METHODS
Isolates. Each isolate originated from a unique clinical specimen. The
MICs of the four triazoles used in the present study for ECV definition
were obtained at one of the followingmedical centers: VCUMedical Cen-
ter, Richmond, VA; Unidad de Microbiologia Experimental, Hospital
Universitario La Fe, Valencia, Spain; Universidad Nacional Autónoma de
México, Mexico; Vallabhbhai Patel Chest Institute, University of Delhi,
Delhi, India; Departamento de Micología, INEI, ANLIS “Dr. Carlos G.
Malbrán,” Buenos Aires, Argentina; Servicio deMicología, CentroNacio-
nal de Microbiología, Instituto de Salud Carlos III, Madrid, Spain;
University of Texas Health Science Center, San Antonio, TX; The Univer-
sity of Alberta, Edmonton, Alberta, Canada; National Institute for Com-
municable Diseases, National Health Laboratory Service, Johannesburg,
South Africa; Department of Medical Microbiology and Infectious
Diseases, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands; In-
stitute of Tropical Medicine Pedro Kouri, Havana, Cuba; The HPA My-
cology Reference Laboratory, Kingsdown, Bristol, United Kingdom;
Women’s and Children’s Hospital, Adelaide, South Australia, Australia;
The Innsbruck Medical University, Innsbruck, Austria; Centers for Dis-
ease Control and Prevention, Atlanta, GA; The Adolfo Lutz Institute Pub-
lic Health Reference Center, São Paulo and Rio Claro, Brazil; Hospital
Universitario de Valme, Sevilla, Spain; University of Texas Health Science
Center, Houston, TX; Hospital General Universitario GregorioMarañón,
Faculty of Medicine-Universidad Complutense, Madrid, Spain; Univer-
sity of Iowa, Iowa City, IA; Duke University Medical Center, Durham,
NC; Institut national de santé publique du Québec, Laboratoire de santé
publique du Québec, Canada; and Instituto de Pesquisa Clinica Evandro
Chagas-FIOCRUZ, Rio de Janeiro, Brazil. Species and molecular type
identification were performed at each medical center using standard
methodologies (8, 11, 25, 28, 33, 36, 51). We have aggregated the maxi-
mum available CLSI data from each laboratory and agent as follows: 2,985
posaconazole, 4,019 itraconazole, 4,693 voriconazole, and 5,733 flucona-
zole MICs for C. neoformans (including MICs for the VNI to VNIV iso-
lates) and 705 posaconazole, 828 itraconazole, 923 voriconazole, and 975
fluconazole MICs for C. gattii (including those for the VGI to VGIV iso-
lates) (8, 11, 24, 25, 26, 33, 36, 51). Sets of 220 (itraconazole) to 359
(fluconazole) MICs obtained using CLSI YNB broth instead of the CLSI
RPMI medium (12) for C. neoformans were also available and analyzed
separately. One or both quality control (QC) isolates (Candida parapsilo-
sis ATCC 22019 and Candida krusei ATCC 6258) were used by the partic-
ipant laboratories (Table 1) (12, 13).
Antifungal susceptibility testing. In order to include MIC results in
the total set of available aggregated CLSI data from the participant labo-
ratories (Tables 2 to 5), triazole MICs were obtained at each center by
following theCLSIM27-A3 brothmicrodilutionmethod (standardRPMI
1640 broth [0.2% dextrose], final inoculum concentrations that ranged
from 0.4 103 to 5 103 CFU/ml, and 72 h of incubation); MICs were
the lowest drug concentrations that produced 50% growth inhibition
compared to the growth control (12). Testing conditions and interpre-
tation of MICs were otherwise identical for those isolates grown in
CLSI YNB broth. MIC data for the two QC reference strains, utilized
during the years of testing in each center, were obtained each time that
a set of isolates was tested following the CLSI M27-A3 broth microdi-
lution method (12, 13).
Definitions.The ECV, a termpreviously used in similar fungal reports
and also known as the COWT, is the highest wild-type (WT) cutoff sus-
ceptible value (19–22, 44). ECVs are based on MIC distributions where
there are two distinct populations: (i) theWTpopulation of isolates/MICs
with no detectable acquired or mutational resistance to the drug being
evaluated and (ii) the non-WT population or isolates that harbor one or
more resistance markers (14, 52). A non-WT organism shows reduced
susceptibility to the agent being evaluated compared to the WT popula-
tion, but it may or may not respond to treatment to the drug being eval-
uated. When data pertaining to the establishment of clinical breakpoints
(CBPs) are not available, ECVs serve as an early indication of emerging
Triazole ECVs for Cryptococcus spp.














changes in the patterns of susceptibility of organisms to the agent being
evaluated.
Data analysis. MIC distributions from each laboratory (laboratories
were coded) for each available combination of triazole and species or
molecular type were listed in Excel spreadsheets before they were aggre-
gated for the analysis. The MIC distributions of each of the four triazoles
for C. neoformans (Tables 2 to 5) were as follows: (i) CLSI RPMI medium
aggregated data from 11 to 18 laboratories for nonmolecular typed iso-
lates (here referred to as nontyped isolates), (ii) CLSI RPMI medium
aggregated data from 2 to 6 laboratories for VNI to VNIVmolecular types
(here referred to as typed isolates), and (iii) single-laboratory CLSI YNB
data. The final WT distributions for C. gattii (Tables 2 to 5) were as fol-
lows: (i) CLSI RPMImedium aggregated data of each of the four triazoles
from4 to 6 laboratories for nontyped isolates and (ii) CLSI RPMImedium
aggregated data from 1 to 7 laboratories for VGI to VGIV (also referred to
as typed isolates). The aggregated MIC distributions obtained in at least












(present study) Modes in g/ml (present study)b
Candida parapsilosis
ATCC 22019
Fluconazole 1–4 (2) 98.1 1–4 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 4, 4, ND
Itraconazole 0.06–0.5 (0.25)b 97.5 0.03–0.5c 0.12, 0.12, 0.12, 0.12, 0.12, 0.12, 0.12, 0.12, 0.12, 0.12, 0.12,
0.12, 0.25, 0.25, ND, ND, ND, ND
Posaconazole 0.03–0.25 (0.12) 98.8 0.03–0.25 0.06, 0.06, 0.06, 0.06, 0.12, 0.12, 0.12, 0.12, 0.12, 0.12, 0.25,
ND, ND, ND, ND, ND, ND, ND
Voriconazole 0.03–0.25 (0.06) 100 0.01–0.25c 0.03, 0.03, 0.03, 0.03, 0.03, 0.03, 0.06, 0.06, 0.06, 0.06, 0.06,
0.06, 0.12, 0.12, 0.12, ND, ND, ND, ND
Candida krusei
ATCC 6258
Fluconazole 16–128 (32) 100 2–64d 16, 32, 32, 32, 32, 32, 32, 32, 32, 32, 32, 32, 64, ND, ND, ND
Itraconazole 0.25–1 (0.5) 100 0.03–1d 0.12, 0.25, 0.25, 0.25, 0.25, 0.25, 0.25, 0.5, 0.5, 0.5, 0.5, ND,
ND, ND, ND, ND, ND
Posaconazole 0.12–1 (0.5) 99.6 0.12–2d 0.12, 0.25, 0.25, 0.25, 0.25, 0.25, 0.25, 0.25, 0.25, ND, ND,
ND, ND, ND, ND, ND
Voriconazole 0.12–1 (0.5) 100 0.12–0.5 0.25, 0.25, 0.25, 0.25, 0.25, 0.25, 0.25, 0.25, 0.5, 0.5, 0.5, 0.5,
ND, ND, ND, ND
a MICs were determined as described by the CLSI M27-A3 document using RPMI 1640 broth (12).
b Modes were not listed for 9 of the 25 laboratories because only 24-h (from 4 to 5 laboratories) or a single (from two to four laboratories) MIC(s) for QC isolates (C. parapsilosis
and C. krusei) were reported for small subsets of isolates (8 to 84 isolates). However, MICs were in range (95 to 100%) and available 24-h modes were within 1 to 2 dilutions. ND,
not determined or obtained using the CLSI YNB broth.
c MICs were outside the range in one (itraconazole [4.5%]) and two (voriconazole [2 to 3%]) laboratories for QC isolate C. parapsilosis ATCC 22019.
d MICs were outside the range in two (fluconazole [0.3 to 5%] and posaconazole [1.5 to 2%]) to four (itraconazole [0.8 to 5%]) laboratories for QC isolate C. krusei ATCC 6258.
TABLE 2 WT fluconazole MIC distributions for the Cryptococcus neoformans-Cryptococcus gattii species complexa
Species or





No. of isolates for which the MIC (g/ml) was:e
0.12 0.25 0.5 1 2 4 8 16 32 64
C. neoformans RPMI N 18 4,446 92 133 258 543 1,225 1,372 569 180 52 22
VNI Y 6 1,137 4 12 40 127 376 456 89 20 10 3
VNII Y 4 42 1 1 1 7 13 12 5 2
VNIII Y 4 54 1 3 9 9 22 8 1 1
VNIV Y 4 54 2 17 19 6 6 2 2
All isolates Both 24 5,733 97 149 319 705 1,629 1,868 668 206 67 25
C. neoformans YNB N 1 359 1 5 13 23 73 84 126 26 8
C. gattii RPMI N 6 137 1 8 19 71 25 6 4 3
VGI Y 7 260 1 18 39 69 101 29 3
VGIIf Y 4 101 3 3 26 32 17 13 7
VGIIa Y 3 200 2 1 16 93 80 6 2
VGIIb Y 2 106 3 9 31 54 9
VGIIc Y 2 42 1 2 21 17 1
All VGII isolates Y 6 449 2 7 28 151 168 53 32 8
VGIII Y 3 43 1 1 6 12 18 4 1
VGIV Y 3 86 2 3 21 19 32 5 4
All isolates Both 10 975 2 24 63 149 360 258 68 40 11
a Fluconazole MICs were determined by the CLSI broth microdilution method (12).
b RPMI and YNB, RPMI 1640 and yeast nitrogen base, respectively, as described by the CLSI M27-A3 document (12).
c Y, yes; N, no.
d Number of laboratories contributing data to each MIC distribution.
e The modal MIC for each distribution is underlined.
f Isolates identified as belonging to the VGII molecular type and not being one of the VGIIa, VGIIb, or VGIIc subtypes examined as a separate group.
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three laboratories were used to calculate ECVs by the statistical method
(52), where the modeled population is based on fitting a normal distribu-
tion at the lower end of the MIC range, working out the mean and stan-
dard deviation of that normal distribution, and using those parameters to
calculate the MIC that captures at least 95%, 97.5%, and 99% of the
modeledWTpopulation (19–22). A search for outlier laboratories in each
distribution was also performed, and only one outlier set of voriconazole
MICs was excluded from the analysis. In addition, ECVs were not esti-
Table 3 WT itraconazole MIC distributions for Cryptococcus neoformans-Cryptococcus gattii species complexa
Species or





No. of isolates for which the MIC (g/ml) was:e
0.008 0.016 0.03 0.06 0.12 0.25 0.5 1 2 4
C. neoformans RPMI N 11 2,731 106 174 377 949 865 222 32 4 2
VNI Y 6 1,145 25 54 147 315 447 144 13
VNII Y 4 32 1 3 3 15 7 2 1
VNIII Y 4 54 1 8 20 14 4 7
VNIV Y 4 57 17 15 9 6 6 4
All isolates Both 20 4,019 26 181 347 736 1,423 1,021 247 32 4 2
C. neoformans YNB N 1 220 1 5 22 38 91 61 1 1
C. gattii RPMI N 5 70 4 9 16 25 12 4
VGI Y 6 257 3 11 42 77 103 20 1
VGIIf Y 3 47 2 13 15 10 6 1
VGIIa Y 2 176 7 15 44 63 41 6
VGIIb Y 2 106 4 5 34 44 14 4 1
VGIIc Y 2 42 1 9 24 7 1
All VGII isolates Y 4 371 4 9 33 94 126 85 18 2
VGIII Y 3 44 1 1 3 14 17 6 2
VGIV Y 3 86 1 1 4 22 24 29 3 2
All isolates Both 9 828 8 5 31 98 232 282 144 24 4
a Itraconazole MICs were determined by the CLSI broth microdilution method (12).
b RPMI and YNB, RPMI 1640 and yeast nitrogen base, respectively, as described by the CLSI M27-A3 document (12).
c Y, yes; N, no.
d Number of laboratories contributing data to each MIC distribution.
e The modal MIC for each distribution is underlined.
f Isolates identified as belonging to the VGII molecular type and not being one of the VGIIa, VGIIb, or VGIIc subtypes examined as a separate group.
Table 4 WT posaconazole MIC distributions for Cryptococcus neoformans-Cryptococcus gattii species complexa
Species or





No. of isolates for which the MIC (g/ml) was:e
0.008 0.016 0.03 0.06 0.12 0.25 0.5 1 2 4
C. neoformans RPMI N 13 2,120 52 152 418 938 440 92 23 5
VNI Y 3 759 21 49 108 334 203 42 2
VNII Y 2 24 1 15 5 2 1
VNIII Y 2 35 2 19 12 2
VNIV Y 2 47 18 11 11 4 3
All isolates Both 15 2,985 21 122 305 780 1,149 486 94 23 5
C. neoformans YNB ND ND
C. gattii RPMI N 4 68 1 8 8 17 20 12 1 1
VGI Y 3 182 3 6 37 64 58 13 1
VGIIf Y 1 5 1 1 1 1 1
VGIIa Y 2 176 7 18 51 62 35 3
VGIIb Y 2 106 5 6 60 31 4
VGIIc Y 2 42 1 3 6 21 11
All VGII isolates Y 2 329 5 1 8 25 115 100 61 14
VGIII Y 2 42 2 14 7 8 10 1
VGIV Y 2 84 2 17 25 28 12
All isolates Both 6 705 9 9 26 93 223 203 113 29
a Posaconazole MICs were determined by the CLSI broth microdilution method (12).
b RPMI and YNB, RPMI 1640 and yeast nitrogen base, respectively, as described by the CLSI M27-A3 document (12).
c Y, yes; N, no.
d Number of laboratories contributing data to each MIC distribution.
e The modal MIC for each distribution is underlined.
f Isolates identified as belonging to the VGII molecular type and not being one of the VGIIa, VGIIb, or VGIIc subtypes examined as a separate group.
Triazole ECVs for Cryptococcus spp.














mated when (i) the distribution was grossly skewed, which precluded
statistical fitting, or (ii) there were data from less than 3 laboratories or the
total number of isolates in a molecular type was less than 50.
RESULTS AND DISCUSSION
The ultimate goal of susceptibility testing is to predict with some
reliability the clinical outcome when an infected patient is treated
with the specific agent evaluated and is referred to as the CBP (14,
30). CBPs are based on the correlation of in vitro data, or theMIC
for the infecting pathogen, with clinical and microbiological out-
comes in order to differentiate an organism as treatable or non-
treatable (14, 30). On the other hand, and as previously defined,
ECVs are based on MIC distributions that comprise the WT and
non-WT populations; the ECV is the highest MIC that belongs to
theWT population. While CBPs predict clinical outcome of ther-
apy, the role of the ECV is to detect emerging resistance or those
non-WT strains with reduced susceptibility (due tomutations) to
the agent being evaluated. Attempts to correlate in vitro flucona-
zole results with clinical outcomehave not been successful (15, 55)
and, to our knowledge, have not been reported for the other three
triazoles. Therefore, CBPs for either C. neoformans or C. gatti in-
fections versus any antifungal agent are not available due to the
paucity of data on PK/PD and clinical outcomes compared to
MICs. However, the ECVs of the four triazoles established in the
present study for C. neoformans and C. gattii may identify the
non-WT clinical isolates and serve as an early indication of emerg-
ing changes in the susceptibility patterns of these organisms. Even
though cryptococcal meningitis and other infections decreased
with the use of antiretroviral therapies in developed countries,
these infections are still a major problem among immunosup-
pressed patients and in certain geographical areas. The triazoles,
especially fluconazole, are primary or salvage therapeutic agents
for cryptococcal infections (2, 38).
Despite standardization efforts, variability is common during
interlaboratory comparisons of MIC results (12, 13). Table 1 de-
picts the MIC data obtained in participant laboratories for one or
both QC isolates (overall range and individual modes), C. parap-
silosis ATCC 22019 and C. krusei ATCC 6258, when clinical iso-
lates were tested. As in previous CLSI ECV studies (19–22), the
majority ofMIC rangeswerewithin theCLSI established limits for
the two QC strains (98%), with a certain degree of interlabora-
tory modal variability (mostly 2-fold dilution); inconsistencies
were more frequent when testing itraconazole, where MICs were
outside the range of 0.8 to 5% for C. parapsilosis ATCC 22019 (1
laboratory) and C. krusei ATCC 6258 (4 laboratories). Intralabo-
ratory reproducibility was excellent in the laboratory using the
CLSI YNB medium (data not shown). Similar modal variability
was also observed among the laboratories for the clinical Crypto-
coccus spp. isolates in this and previous multicenter studies estab-
lishing ECVs of several antifungal agents for Aspergillus spp. and
Cryptococcus spp. (19–22). The most probable reason is the indi-
vidual interpretations of MIC endpoints, and/or it may be due to
the use of different lots of antifungal powders.
The aggregated MIC distributions of the four triazoles for C.
neoformans and C. gattii (for nontyped and typed isolates) are
depicted in Tables 2 to 5, which also list single-laboratory distri-
butions for C. neoformans (CLSI YNB data). Fluconazole modal
MICs measured in RPMI medium were 1 to 4 g/ml for C. neo-
formans typed and nontyped isolates, with the lowest mode for
VNIV.Modes were consistently higher among theC. gattii groups
(4 to 16g/ml), with the highest for VGIIc (Table 2). Fluconazole
modes from individual contributing laboratories were either 2 or
Table 5 WT voriconazole MIC distributions for Cryptococcus neoformans-Cryptococcus gattii species complexa
Species or





No. of isolates for which the MIC (g/ml) was:e
0.008 0.016 0.03 0.06 0.12 0.25 0.5 1 2 4
C. neoformans RPMI N 12 3,473 34 412 814 1,090 748 252 92 20 6 5
VNI Y 5 1,089 35 48 100 385 376 119 19 5 1 1
VNII Y 3 27 5 6 9 3 4
VNIII Y 3 51 9 7 19 12 3 1
VNIV Y 3 53 13 19 12 6 2 1
All isolates Both 22 4,693 69 487 946 1,515 1,145 380 113 25 7 6
C. neoformans YNB N 1 281 35 78 105 53 10
C. gattii RPMI N 5 98 2 7 13 37 23 11 5
VGI Y 6 258 3 13 38 69 90 45
VGIIf Y 3 96 1 1 29 38 23 4
VGIIa Y 3 197 6 3 47 113 23 3 2
VGIIb Y 2 106 3 2 6 46 47 2
VGIIc Y 2 42 1 2 7 19 11 2
All VGII isolates Y 5 441 3 7 7 84 204 112 20 4
VGIII Y 2 42 1 3 12 21 5
VGIV Y 2 84 8 28 29 16 3
All isolates Both 9 923 8 28 69 230 367 189 28 4
a Voriconazole MICs were determined by the CLSI broth microdilution method (12).
b RPMI and YNB, RPMI 1640 and yeast nitrogen base, respectively, as described by the CLSI M27-A3 (12).
c Y, yes; N, no.
d Number of laboratories contributing data to each MIC distribution.
e The modal MIC for each distribution is underlined.
f Isolates identified as belonging to the VGII molecular type and not being one of the VGIIa, VGIIb, or VGIIc subtypes examined as a separate group.
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4 g/ml for C. neoformans nontyped and most typed isolates; the
exception was the mode (1 g/ml) from two of the four laborato-
ries that contributed data for VNIV, but the number of isolates
was small. Overall, our values reflect previous fluconazoleMIC90s
andmodes for similar sets of typed or nontypedC. neoformans and
C. gattii isolates and the fact thatMICs are usually higher (MIC90s
and modes, 2 to 8 g/ml versus 8 to 32 g/ml) for C. gattii inde-
pendent of testing conditions (10, 16, 23, 50).However, theMIC90
has also been higher (16g/ml) forC. neoformans nontyped isolates
(5, 39), but some of those results were obtained by the EUCAST
method (39). The modal MIC for C. neoformansmeasured in CLSI
YNB medium was higher (mode, 8 g/ml) than those measured in
CLSI RPMI medium; this discrepancy has been reported previously
(10, 55). These results further underline the variability of susceptibil-
ity test results using different methodologies.
Modes for the other three triazoles were more species-, molec-
ular type- and medium-dependent (Tables 3 to 5). In agreement
with previous data (10, 16, 23, 50), the MICs of itraconazole, po-
saconazole, and voriconazole for C. gattii also tended to be higher
(modes, 0.06 to 0.5 g/ml, typed and nontyped isolates) than
those for C. neoformans (modes, 0.016 to 0.12 g/ml, typed and
nontyped isolates), with the highest modes for VGIIb and VGIIc
(voriconazolemode, 0.25g/ml) and VGIIc and VGIV (itracona-
zole and posaconazole mode, 0.5 g/ml) (Tables 3 to 5). Reflect-
ing fluconazole distributions, modes from individual participant
laboratories were within one dilution of each other (modes, 0.12
to 0.25 g/ml and 0.06 to 0.12 g/ml for itraconazole and both
posaconazole and voriconazole, respectively). Based on these data
and the wide geographical range over which the MICs have been
collected in the present study, we surmise that we are presenting
valid data.
Table 6 depicts the proposed fluconazole, itraconazole, po-
saconazole, and voriconazole ECVs for the aggregated distribu-
tions of C. neoformans and C. gattii (typed or nontyped isolates).
ECVs were proposed when the data originated from at least three
laboratories using the statistical methodology that comprised
95% of the modeled population instead of the observed popu-
lation; the values that comprised 97.5 and 99% of the popu-
lation were also obtained. Some of the proposed ECVs were based
on small numbers of isolates (Tables 2 to 5, n 100), and those
could be considered tentative values. Although three other distri-
butions (fluconazole versus VNIV and itraconazole versus VNIII
and VNIV) originated in at least three laboratories, statistical fit-
ting was not possible and ECVs were not proposed. The CLSI
TABLE 6 ECVs and percentages of isolates of the Cryptococcus neoformans-Cryptococcus gattii species complex above each triazole WT distribution
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C. neoformans Nontyped isolates Fluconazole 4 16 (1.7) 16 (1.7) 32 (0.5)
Itraconazole 0.12 0.5 (1.1) 1 (0.2) 1 (0.2)
Posaconazole 0.12 0.25 (5.7) 0.5 (1.3) 0.5 (1.3)
Voriconazole 0.06 0.25 (3.5) 0.25 (3.5) 0.5 (0.9)
VNI Fluconazole 4 8 (2.9) 8 (2.9) 16 (1.1)
Itraconazole 0.12 0.25 (1.1) 0.5 (0) 0.5 (0)
Posaconazole 0.06 0.25 (0.3) 0.25 (0.3) 0.25 (0.3)
Voriconazole 0.06 0.25 (2.4) 0.25 (2.4) 0.5 (0.6)
VNIII Fluconazole 4 16 (1.9) 16 (1.9) 32 (0)
Voriconazole 0.06 0.25 (2) 0.25 (2) 0.5 (0)
VNIV Voriconazole 0.03 0.12 (5.7) 0.12 (5.7) 0.12 (5.7)
C. gattii Nontyped isolates Fluconazole 4 8 (9.5) 8 (9.5) 16 (5.1)
Itraconazole 0.12 0.5 (0) 0.5 (0) 1 (0)
Posaconazole 0.12 0.5 (1.5) 0.5 (1.5) 1 (0)
Voriconazole 0.06 0.25 (5.1) 0.5 (0) 0.5 (0)
VGI Fluconazole 4 8 (1.2) 16 (0) 16 (0)
Itraconazole 0.25 0.5 (0.4) 0.5 (0.4) 1 (0)
Posaconazole 0.12 0.5 (0.5) 0.5 (0.5) 1 (0)
Voriconazole 0.12 0.5 (0) 0.5 (0) 1 (0)
VGII Fluconazole 8 32 (6.9) 32 (6.9) 64 (1)
Itraconazole 0.12 0.5 (2.1) 0.5 (2.1) 1 (0)
Voriconazole 0.12 0.25 (4.1) 0.5 (0) 0.5 (0)
VGIIa Fluconazole 4 8 (4) 16 (1) 16 (1)
Voriconazole 0.12 0.25 (2.5) 0.25 (2.5) 0.25 (2.5)
VGIII Fluconazole 4 8 (2.3) 8 (2.3) 16 (0)
Itraconazole 0.25 0.5 (4.5) 1 (0) 1 (0)
VGIV Fluconazole 8 16 (4.7) 32 (0) 32 (0)
Itraconazole 0.5 1 (2.3) 1 (2.3) 2 (0)
a Data from laboratories using the CLSI RPMI broth (12).
b Mode, MIC most frequently obtained for each distribution.
c Calculated ECVs comprising95%,97.5%, or99% of the statistically modeled population for which MIC distributions originated in at least three laboratories.
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fluconazole ECVs for the different subsets of C. neoformans iso-
lates were either 8g/ml (VNI) or 16g/ml (nontyped andVNIII
isolates). Fluconazole ECVs for C. gattii ranged from 8 g/ml
(nontyped, VGI, VGIIa, andVGIII isolates) to 32g/ml (VGII). It
is interesting that a fluconazole MIC of16 g/ml is anecdotally
believed to be the resistance cutoff, but this value can be perceived
here as a non-WT value for some of the subsets of the two species.
So far mutations have not been observed when the fluconazole
MIC is16g/ml (49). ECVs of the three other triazoleswere also
species-, agent-, andmolecular type-dependent as follows: (i) itra-
conazole ECVs of 0.25g/ml (VNI), 0.5g/ml (nontyped isolates
of both species and VGI to VGIII), and 1 g/ml (VGIV); (ii)
posaconazole ECVs of 0.25 g/ml (C. neoformans nontyped and
VNI) and 0.5 g/ml (C. gattii nontyped and VGI); and (iii) vori-
conazole ECVs of 0.12 g/ml (VNIV), 0.25 g/ml (nontyped iso-
lates of both species, VNI,VNIII, VGII, andVGIIa), and 0.5g/ml
(VGI). The overall trend was that ECVs for C. neoformansmolec-
ular types were lower than those forC. gattii. PreviousMIC90s and
modes of these three triazoles have been similar (9, 10, 23, 44, 50).
Because the distributions in CLSI YNB originated from a single
laboratory, ECVs were not proposed for these distributions (Ta-
bles 2, 3, and 5). Tentative values of 16 g/ml for fluconazole
(encompassing 97.8% of the isolates), 2 g/ml for itraconazole
(encompassing 99.5%of the isolates), and 0.5g/ml for voricona-
zole (encompassing 100% of the isolates) can be suggested for
CLSI YNB MICs (data not shown). Additional data from other
laboratories using either CLSI YNB or CLSI RPMI medium (at
least three laboratory subsets), or for subsets comprising at least
100 isolates, should corroborate/extend our tentative values.
ECVs encompassing both 97.5% and 99% of the modeled
populationweremostly the same or one dilution higher (Table 6);
the same applied when all isolates of each species were pooled
together, e.g., all VGIIs (data not shown). Although the proposed
ECVs in the present study are not predictors of clinical outcome,
these critical drug concentrations may aid in identifying those
cryptococcal strains with decreased susceptibility to the triazole
being evaluated.
The frequency of MICs above the ECV (non-WT) varied ac-
cording to the distribution analyzed (Table 6). The rate of flu-
conazole non-WTMICswas higher (1.7 to 9.5%) than those of the
other three triazoles (0 to 5.7%). Between the two species, the
fluconazole and itraconazole rates of non-WTMICs were usually
lower for all C. neoformans isolates (1.1 to 2.9%) than for all C.
gatti isolates (0 to 9.5%) and almost the same for voriconazole. In
contrast, the rate was lower for posaconazole (0.3 to 5.7% versus
0.5 to 1.5%). However, C. gattii MIC distributions were small
(Tables 2 to 5). Although cryptococcal infections caused by both
species are clinically similar, there is more of a delayed treatment
response and other complications in infections caused by C. gattii
than those due to C. neoformans (38). In vitro resistance to flu-
conazole (3.1% to 46%) and itraconazole (0.5% to 17.4%) has
been reported for C. neoformans isolates; although the itracona-
zole cutoff was 1 g/ml, it was variable for fluconazole (16
g/ml and 64 g/ml) (5, 16, 39). Based on arbitrary voricona-
zole cutoffs of2 g/ml for both Cryptococcus spp., in vitro resis-
tance to this agent has been low or absent (0% to 0.9%) (23, 24, 43,
50); the same applies to posaconazole (23, 24, 43). Species identi-
fication and antifungal susceptibility testing emphasize the utility
ofWTcutoffs as a practical tool to detect triazole resistance among
Cryptococcus isolates. Our results also point out that ECVs should
be species-specific and, for this fungal group, molecular type-spe-
cific. This information is important; it has been reported that 20%
of cryptococcal infections are caused by multiple strains or mo-
lecular types, but generally only one isolate per infection is tested
(17).
During the 1990s, the early years of fluconazole therapy, re-
lapses were not associatedwith in vitro resistance due to the higher
initial fluconazole doses (38). Since then, relapses have been at-
tributed to the excessive use of this agent as primary and prophy-
lactic therapies, as well as the use of suboptimal doses for long
periods of time, especially amongAIDSpatients. As relapses began
to be associated with high fluconazole MICs and/or a 4-fold MIC
increase (1, 24, 37, 38), several aspects of sterol metabolism in
these isolates were investigated to determine azole resistance
mechanisms in C. neoformans. A point mutation in the ERG11
(CnCYP51) gene resulting in a G484S substitution in the target
enzyme has been observed in C. neoformans strains with high flu-
conazole MICs (32 g/ml); this mutation alters the affinity of
the drug for the target enzyme (32, 48, 54). The overexpression of
the gene CnAFR1 that encodes the membrane efflux pumps has
been found to reduce cell drug (fluconazole) content in C. neofor-
mans (29, 45). Azole cross-resistance among cryptococcal strains
is rare; the lack of cross-resistance between itraconazole and flu-
conazole has been attributed to the dual itraconazole target in C.
neoformans, which appears to block both the lanosterol 14--de-
methylase and the NADH-dependent 3-ketosteroid reductase
(37). Thiswas recently confirmed in aC. neoformans isolate, where
cross-resistance was evident between fluconazole (MICs 64g/
ml) and voriconazole (MICs  2 g/ml) but not with itracona-
zole. In contrast, increased itraconazole susceptibility (lower
MIC) andno change in the posaconazoleMICwere observed (49).
A missense mutation (Y145F substitution) in the ERG11 gene
(P450Dm, ERG11) led to fluconazole-voriconazole cross-resistance.
In addition, a high level of heteroresistance to fluconazole, more
commonly observed inC. gattii than inC. neoformans isolates, was
observed in the same isolate (49, 53). Some of these findings ex-
plain the different rates of non-WT isolates found in the present
study.
Based on small numbers of patients/isolates and the use of
different methodologies, correlations between a variety of flu-
conazole MICs and clinical outcomes (1, 3, 34) have been re-
ported: more rapid CSF sterilization and infection eradication has
been associated with MICs of 4 to 8 g/ml and clinical failure or
recurrence with MICs of16 g/ml. In addition, either a lack of
correlation (15) or a relationship that was dependent on the com-
bination of high MICs with other factors have been documented
(55). A more useful MIC cutoff that would predict azole failure in
treatment of cryptococcal infections has also been hampered by
other factors that influence outcome to therapy in addition to
microbiological clearance (17, 37). Conversely, our ECVs could
aid in the separation of WT strains from those with reduced azole
susceptibility or non-WT isolates. However, more information is
needed regarding azole resistance in C. neoformans and C. gattii,
especially for posaconazole and voriconazole, as well as the rela-
tionship between non-WT strains and resistance mechanisms.
In conclusion, the ECVs of fluconazole (8 to 32 g/ml), itra-
conazole (0.25 to 1g/ml), posaconazole (0.25 to 0.5g/ml), and
voriconazole (0.12 to 0.25g/ml) proposed in this study for theC.
neoformans-C. gattii species complex are species- and molecular
type-specific, but these differences were mostly within one dilu-
Espinel-Ingroff et al.














tion. Further investigation should determine the relationship be-
tween molecular mechanisms of triazole resistance and our pro-
posed non-WT values. Some of the distributions were small
(especially for various C. neoformans molecular types), and con-
tinuing surveillance should either corroborate or expand the in-
formation provided in the present study. In the absence of CBPs,
these ECVs may be clinically useful in detecting non-WT isolates
that have reduced susceptibility to itraconazole, posaconazole,
and voriconazole or that harbor fluconazole resistance mecha-
nisms. ECVs should be included in the revised version of the CLSI
M27-A3 document.
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